Many people with fragile X syndrome show average rates of protein production, challenging a long-held assumption about the condition.

The drug mavoglurant has no effect on a brain circuit involved in social behavior in a mouse model of fragile X syndrome. That may explain its poor performance in people with the condition.

A drug that selectively blocks one form of an enzyme called GSK-3 prevents seizures and improves cognitive deficits in a mouse model of fragile X syndrome.

Clinical trials for autism drugs have been plagued with problems: bad design, the wrong measures, too broad a range of participants. All that is finally starting to change.

Our infographic displays efforts to develop treatments for fragile X syndrome. So far, none of them have passed muster in clinical trials.

Watch the complete replay of Sébastien Jacquemont discussing cognitive, behavioral and neural changes underlying the link between genes and conditions such as autism.

The fight over who holds the rights to CRISPR is heating up, we control our gut bacteria, and romance isn’t always easy when you have autism.

Blocking an enzyme involved in learning and memory corrects brain abnormalities and improves memory in fly and mouse models of fragile X syndrome.

A human gene gives mice bigger brains, and people with autism weigh in on that white or blue dress.

Drugs designed to treat fragile X syndrome have yet to show substantial benefits in people. But rather than abandon them, child neurologist Elizabeth Berry-Kravis suggests a new way to measure their effectiveness.